Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;39(8):2489-2490.
doi: 10.1007/s10067-020-05232-y. Epub 2020 Jun 20.

The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al

Silvia Piantoni  1   2 , Enrico Colombo  3 , Paolo Airò  4 , Angela Tincani  4   5 , Antonio Brucato  6 , Franco Franceschini  4   5 , Laura Andreoli  4   5 , Roberto Furloni  3 , Mirko Scarsi  3
Affiliations
Comment

The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al

Silvia Piantoni et al. Clin Rheumatol. 2020 Aug.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Cumhur Cure M, Kucuk A, Cure E. Colchicine may not be effective in COVID-19 infection; it may even be harmful? Clin Rheumatol. 2020;39:2101–2102. doi: 10.1007/s10067-020-05144-x. - DOI - PMC - PubMed
    1. Piantoni S, Patroni A, Toniati P et al (2020) Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease. Rheumatology. 10.1093/rheumatology/keaa217 - PMC - PubMed
    1. Mehta P, McAuley DF, Brown M, On behalf of the HLH Across Speciality Collaboration, UK et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0. - DOI - PMC - PubMed
    1. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2:e325–e331. doi: 10.1016/S2665-9913(20)30127-2. - DOI - PMC - PubMed
    1. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, Franceschini F, Airò P, Bazzani C, Beindorf EA, Berlendis M, Bezzi M, Bossini N, Castellano M, Cattaneo S, Cavazzana I, Contessi GB, Crippa M, Delbarba A, de Peri E, Faletti A, Filippini M, Filippini M, Frassi M, Gaggiotti M, Gorla R, Lanspa M, Lorenzotti S, Marino R, Maroldi R, Metra M, Matteelli A, Modina D, Moioli G, Montani G, Muiesan ML, Odolini S, Peli E, Pesenti S, Pezzoli MC, Pirola I, Pozzi A, Proto A, Rasulo FA, Renisi G, Ricci C, Rizzoni D, Romanelli G, Rossi M, Salvetti M, Scolari F, Signorini L, Taglietti M, Tomasoni G, Tomasoni LR, Turla F, Valsecchi A, Zani D, Zuccalà F, Zunica F, Focà E, Andreoli L, Latronico N. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19:102568. doi: 10.1016/j.autrev.2020.102568. - DOI - PMC - PubMed